Binds androgen receptor as partial agonist — selectively induces AR coactivator recruitment profile distinct from DHT. Simultaneously induces follistatin expression in muscle cells, suppressing myostatin signaling. Two distinct pro-anabolic mechanisms in one molecule. Steroidal backbone differs from non-steroidal SARMs.
Studies have administered: No established human research doses; animal and in vitro studies only; case reports of 5–10mg/day in experimental contexts
Kanno et al. (2011): original in vitro study showing myogenic differentiation enhancement. Follistatin induction confirmed in C2C12 cells. No completed human clinical trials. Animal pharmacology promising but human data lacking.
Insufficient human data; androgen receptor activity suggests testosterone suppression, cardiovascular lipid changes, hepatotoxicity risk from oral steroidal structure
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on YK-11 — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat